- Home
- NTIC vs CRDF Comparison
NTIC vs CRDF Comparison
Compare NTIC & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTIC
- CRDF
- Stock Information
- Founded
- NTIC 1970
- CRDF 1999
- Country
- NTIC United States
- CRDF United States
- Employees
- NTIC N/A
- CRDF N/A
- Industry
- NTIC Industrial Specialties
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NTIC Industrials
- CRDF Health Care
- Exchange
- NTIC Nasdaq
- CRDF Nasdaq
- Market Cap
- NTIC 71.5M
- CRDF 210.2M
- IPO Year
- NTIC N/A
- CRDF N/A
- Fundamental
- Price
- NTIC $8.47
- CRDF $3.66
- Analyst Decision
- NTIC Buy
- CRDF Strong Buy
- Analyst Count
- NTIC 1
- CRDF 5
- Target Price
- NTIC $20.00
- CRDF $10.50
- AVG Volume (30 Days)
- NTIC 84.4K
- CRDF 1.5M
- Earning Date
- NTIC 07-10-2025
- CRDF 08-07-2025
- Dividend Yield
- NTIC 3.38%
- CRDF N/A
- EPS Growth
- NTIC N/A
- CRDF N/A
- EPS
- NTIC 0.38
- CRDF N/A
- Revenue
- NTIC $84,445,763.00
- CRDF $587,000.00
- Revenue This Year
- NTIC $2.05
- CRDF N/A
- Revenue Next Year
- NTIC $4.70
- CRDF N/A
- P/E Ratio
- NTIC $21.69
- CRDF N/A
- Revenue Growth
- NTIC 2.11
- CRDF N/A
- 52 Week Low
- NTIC $6.75
- CRDF $2.01
- 52 Week High
- NTIC $16.58
- CRDF $5.64
- Technical
- Relative Strength Index (RSI)
- NTIC 62.23
- CRDF 58.81
- Support Level
- NTIC $7.37
- CRDF $3.07
- Resistance Level
- NTIC $8.43
- CRDF $3.24
- Average True Range (ATR)
- NTIC 0.36
- CRDF 0.23
- MACD
- NTIC 0.11
- CRDF 0.00
- Stochastic Oscillator
- NTIC 74.34
- CRDF 67.96
About NTIC Northern Technologies International Corporation
Northern Technologies International Corp, or NTIC is a United States-based firm that develops and markets environmentally beneficial products and services world-wide either directly or through a network of joint ventures, distributors, and agents. It operates through two segments which include ZERUST products and services and Nature-Tec products. Its main business is providing corrosion prevention solutions that are marketed under the ZERUST brand. The company also sells a portfolio of bio-based and biodegradable (compostable) polymer resin compounds and finished products marketed under the Nature-Tec brand. The ZERUST brand generates a vast majority of the revenue for the company.
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.